StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen non-GAAP R&D Expense as % of Product Sales (%) (%)

Form 8-K Reconciliations of GAAP to Non-GAAP Measures

QuarterlyAnnual
Latest, Q2 2026
19.4%
Period ended Jun 30, 2026
Change on a year earlier
+0.2 pts
19.2% in Q2 2025
History
36 quarters
Since Q3 2017
Sources
32
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP R&D Expense as % of Product Sales (%) (%)Year on yearSource
Q2 2026Jun 30, 202619.4%+0.2 ptsForm 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202620.8%+2.1 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202522.8%+3.3 ptsForm 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202520.7%+3.0 ptsForm 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202519.2%+1.5 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 202518.7%+0.2 ptsForm 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202419.5%+0.4 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202417.7%+1.4 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202417.7%+1.4 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202418.5%+0.6 ptsForm 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202319.1%-0.6 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202316.3%-1.3 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202316.3%+0.1 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202317.9%+1.6 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202219.7%-1.3 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202217.6%+1.8 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up non-gaap r&d expense as % of product sales (%)

Cite this data

StockData. (2026). Amgen Non-GAAP R&D Expense as % of Product Sales (%) (%), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng_rd_pct

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.